12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

HyQvia regulatory update

Baxter resubmitted a BLA to FDA for HyQvia as replacement therapy to treat adults with primary immunodeficiency associated with defects in humoral immunity. The resubmission contains preclinical data requested by FDA...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >